Incyte Corporation (INCY) Stock Analysis
A live, multi-source view of Incyte Corporation (INCY): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Sector: Healthcare · Industry: Biotechnology · United States · 2,844 employees · incyte.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Incyte Corporation (INCY) had a market capitalization of $25.69B, a trailing P/E of 16.1 (forward 14.3) and a beta of 0.77; the shares traded in a 52-week range of $81.09 – $132.60 (46.4% over the year).
- Market cap
- $25.69B
- Enterprise value
- $21.19B
- Trailing P/E
- 16.1
- Forward P/E
- 14.3
- PEG ratio
- 10.74
- Price / book
- 4.02
- EPS (trailing)
- $7.85
- EPS (forward)
- $8.89
- Payout ratio
- 0.0%
- 52-week range
- $81.09 – $132.60
- 52-week change
- 46.4%
- Beta
- 0.77
- Average volume
- 1.8M
- Shares outstanding
- 202.7M
- Short % of float
- 7.90%
- Profit margin
- 27.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Incyte Corporation (INCY) last closed at $126.75 (the last completed close before that scan).
Technicals at the scan: RSI 56 (neutral territory), price +1.2% versus its 20-day average, 20-day versus 50-day average spread +3.6%, MACD histogram -0.28.
Sentiment inputs: 75% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 62/100.
Next scheduled company event: in 49 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of INCY; corporate insiders filed 0 buys and 2 sells (2 distinct filers, latest disclosure 2026-07-20). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Steven H. Stein (0B/1S), Mohamed Khairie Issa (0B/1S). Who is trading what
RapidTradeView pick record
INCY has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Incyte Corporation (INCY) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell INCY.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.